Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings
29.10.2025 03:13
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close. Here’s what to expect.
Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics
27.10.2025 13:15
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
What To Expect From Gilead In Q3 2025
24.10.2025 10:56
Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting. Check out why GILD stock is a strong buy.
LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
21.10.2025 11:00
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA alone, or as monotherapy in patients unable to tolerate UDCA. This market authorization has been issued with conditions pending the results of trials to verify its clinical benefit.
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
21.10.2025 10:30
WASHINGTON, October 21, 2025--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
13.10.2025 12:30
FOSTER CITY, Calif., October 13, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for Medical Oncology (ESMO) 2025 Congress October 17 – 21.
RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD)
03.10.2025 10:28
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical stocks to buy now. RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences, Inc. (NASDAQ:GILD) on September 29 and set a price target of $98.00. Gilead Sciences, Inc. (NASDAQ:GILD) reported a 2% growth in its total revenues for fiscal Q2 2025 to $7.1 […]
Gilead Foundation Commits Over $6.5M in New Grant Funding to Support STEM Education Pathways
03.10.2025 09:33
Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued stocks to buy and hold for 5 years. On September 25, Gilead Sciences announced that its Gilead Foundation has committed more than $6.5 million in new grant funding to strengthen Science, Technology, Engineering, and Math/STEM education pathways. The funding is part of an ongoing commitment […]
3 Way-Too-Early Predictions For 2026
03.10.2025 08:24
Markets continue to advance despite continuing concerns around valuations, inflation, and the deteriorating jobs market. Read what investors need to know.
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
29.09.2025 12:48
Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") for encequidar, a first-in-class P-glycoprotein ("P-gp") inhibitor in the field of virology.
Hanmi's Oral Delivery Platform Compound Licensed to Gilead
29.09.2025 09:45
Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") and Health Hope Pharma ("HHP") granting Gilead the exclusive rights to develop and commercialize encequidar.
Morgan Stanley Maintains Buy on Gilead Sciences (GILD)
29.09.2025 05:39
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 21, Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $143. The analyst noted that the US CDC recently recommended the company’s Yeztugo for HIV […]
3 Unpopular Stocks We Approach with Caution
29.09.2025 04:34
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating
26.09.2025 14:48
Gilead Sciences, Inc. (NASDAQ:GILD) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks. On September 16, JPMorgan analyst Chris Schott lifted the stock’s price target to $145 from $135 while maintaining an Overweight rating for its shares. While the firm left most of its large-cap biopharma estimates unchanged, it adjusted share price targets on a move […]
Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer
18.09.2025 12:00
Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the completion of the safety run-in and the determination of recommended Phase 2 dose (RP2D) for its ongoing Phase 1b/2 STARt-002 trial. The study, evaluating Marengo's dual T-cell agonist invikafusp alfa in combination with TRODELVY® (sacituzumab govitecan-hziy), Gilead's approved TROP2-directed antibody-drug c
Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management
18.09.2025 02:16
SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Sciences, Inc.’s (“Gilead”) 2025 Multi-Channel Conference in Shanghai. Founder, Chairman and CEO Dr. Xie Fangmin was invited as a keynote guest at the event. The award recognizes Fangzhou’s achievements in advancing innovation and digitalization in healthcare, underscoring its shared commitment with Gil
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
17.09.2025 12:00
Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are being presented at the European Academy of Dermatology and Venereology (EADV) Congress SAN FRANCISCO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as part of the company’s ongoing rese
Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
09.09.2025 14:16
Get the latest on Gilead Sciences' growth, HIV and oncology pipeline, and PrEP innovation
Gilead Sciences advances HIV prevention with new US partnership
05.09.2025 10:00
Gilead plans to submit regulatory filings for lenacapavir for PrEP in 18 nations.
Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks
05.09.2025 09:07
Pfizer Inc.'s strong Q2 2025 sales defy expectations. Discover analyst insights, growth drivers, and why it's rated Strong Buy. Click for my PFE stock update.